Hansen Medical Announces the Filing of 30 New U.S. Patent Applications Related to Flexible Medical Robotics
01 4월 2013 - 9:00PM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in
intravascular robotics, today announced that it has recently filed
30 new patent applications with the U.S. Patent and Trademark
Office relating to flexible medical robotics, based on research and
development activities conducted by the Company. With these new
filings, Hansen Medical now owns or has exclusive rights to
approximately 250 issued and pending patent applications relating
to medical robotics, in addition to hundreds of other related
patents and patent applications which the Company has the right to
use under various third party license agreements.
"Thanks to our talented, innovative and dedicated engineers and
scientists, the level of invention has never been higher at Hansen
Medical than it is today," said Bruce Barclay, president and CEO of
Hansen Medical. "These new patent applications relate to not only
our core intravascular robotics technology, but also other possible
clinical applications of our technology, and a number of different
technical elements critical to the clinical success of medical
robotics, including robotic systems, software, flexible
instruments, sensing, navigation, and imaging. I am more confident
than ever that our intellectual property portfolio, as supplemented
by these new filings, will provide us an even stronger proprietary
position for our current and future products, and increased
potential to grow shareholder value, for years to come."
"The creativity consistently demonstrated by our technical
teams, supported by our significant investment in R&D, which
resulted in these new filings, has been exceptional," said Will
Sutton, COO of Hansen Medical. "The Company has never filed this
many new U.S. patent applications in a single year in its history,
let alone this early in the year, making this accomplishment all
the more impressive."
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, is the global leader in
intravascular robotics, developing products and technology designed
to enable the accurate positioning, manipulation and control of
catheters and catheter-based technologies. The Company's Magellan™
Robotic System, Magellan Robotic Catheter and related accessories,
which are intended to facilitate navigation to anatomical targets
in the peripheral vasculature and subsequently provide a conduit
for manual placement of therapeutic devices, have undergone both CE
marking and 510(k) clearance and are commercially available in the
European Union, and the U.S. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan Control Catheter are
cleared for use during electrophysiology (EP) procedures, such as
guiding catheters in the treatment of atrial fibrillation (AF), and
the Lynx® Robotic Ablation Catheter is cleared for the treatment of
AF. This robotic catheter system is compatible with fluoroscopy,
ultrasound, 3D surface map and patient electrocardiogram data. In
the U.S. the Company's Sensei X Robotic Catheter System and Artisan
Control Catheter were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in EP procedures. In the United States, the Sensei System
is not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X System and
Artisan Control Catheter for use with cardiac ablation catheters in
the treatment of cardiac arrhythmias, including AF, have not been
established. Additional information can be found at
www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements regarding, among other
things, statements relating to goals, plans, objectives, milestones
and future events. All statements, other than statements of
historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "plan," "expects," "potential," "believes," "goal,"
"estimate," "anticipates," and similar words. These statements are
based on the current estimates and assumptions of our management as
of the date of this press release and are subject to risks,
uncertainties, changes in circumstances and other factors that may
cause actual results to differ materially from the information
expressed or implied by forward-looking statements made in this
press release. Examples of such statements include statements about
the potential benefits of our technology and the value of our
intellectual property portfolio. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, among others: engineering,
regulatory, manufacturing, sales and customer service challenges in
developing new products and entering new markets; potential safety
and regulatory issues that could slow or suspend our sales; the
effect of credit, financial and economic conditions on capital
spending by our potential customers; the uncertain timelines for
the sales cycle for newly introduced products; the rate of adoption
of our systems and the rate of use of our catheters; the scope and
validity of intellectual property rights applicable to our
products; competition from other companies; our ability to recruit
and retain key personnel; our ability to maintain our remedial
actions over previously reported material weaknesses in internal
controls over financial reporting; our ability to manage expenses
and cash flow, and obtain additional financing; and other risks
more fully described in the "Risk Factors" section of our Annual
Report on Form 10-K for the year ended December 31, 2012 filed with
the SEC on March 18, 2013 and the risks discussed in our other
reports filed with the SEC. Given these uncertainties, you should
not place undue reliance on the forward-looking statements in this
press release. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the
future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart
Design), Sensei and Lynx are registered trademarks, and Magellan
and NorthStar are trademarks of Hansen Medical, Inc. in the United
States and other countries.
Investor Contacts: Peter J. Mariani Chief Financial
Officer Hansen Medical, Inc. 650.404.5800 FTI Consulting,
Inc. Brian Ritchie 212.850.5683 Email Contact John Capodanno
212.850.5705 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024